.
Fichier Détails
| Cartes-fiches | 51 |
|---|---|
| Langue | Deutsch |
| Catégorie | Gestion d'entreprise |
| Niveau | École primaire |
| Crée / Actualisé | 27.02.2016 / 28.02.2016 |
| Lien de web |
https://card2brain.ch/box/nn_background
|
| Intégrer |
<iframe src="https://card2brain.ch/box/nn_background/embed" width="780" height="150" scrolling="no" frameborder="0"></iframe>
|
explain the four phases within the product pipeline
see image
How doeas GLP 1 works?
Glucagon-like peptide-1 (GLP-1) is produced by the gut and the brain in response to eating. GLP-1 interacts with
the pancreas to increase the amount of insulin in the body. It stimulates insulin secretion in the beta cells in the
pancreas and reduces glucagon in the alpha cells. It does so in a glucose-dependent manner, which helps lower
fasting and postprandial blood glucose. At the same time, GLP-1 increases feelings of satiety and reduces feelings
of hunger – leading to a reduction in food intake.
What are the main seven risks for NN?
Delays or failure of pipeline products
Market risks
supply distributions
quality and product safety issues
IT risks
business ethics and lega risks
financial risks
What is NN market cap, 1y total return, dividend yield and historical beta?
market cap:927'680m
1y total return: 13,23%
dividend yield: 1,79%
beta: 1,19
Key ratios: EV/Sales, EV/EBITDA, EV/EBIT, P/E, ROA, ROE, Price to Book Value
EV/Sales 8.4
EV/EBITDA 17.3
EV/EBIT 18.3
P/E 26.3
Price to Book Value 19.7
ROA 50.7
ROE 79.9
Last corporate Event?
42.02.16 Novo Nordisk A/S Tresiba Phase 3b Trial Results Corporate Call
An M&A deal last year
27.08.15 calibrium llc: Novo Nordisk today announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US.
Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk 's portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk 's research presence in the US.
Market shares of diabetes care devices
see image
What are the top ten market players adn how does the 2020 projection looks like?
see image
Who are the top 3 shareholders?
Novo A/S: 7.94
Capital World Investors: 5.48
Capital International Investors: 2.73
Latest news?
23.02.16: Novo Nordisk A/S says trial with Tresiba met primary end-point. Tresiba demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes.Says trial met primary end-point by demonstrating non-inferiority in rate of severe or blood glucose confirmed symptomatic hypoglycemia of Tresiba compared to insulin glargine.Says expect to initiate filing of data from switch trials with regulatory authorities in Q3 2016 with aim of updating label for Tresiba.
